A+ Human Blood and Plasma Cells

A+ Human Blood and Plasma Cells
for
Walter Reed Army Institute of Research (WRAIR)

General Information:

This is a Request for Information (RFI) as defined in FAR 15.201(e) to ascertain whether a commercial item exists that provides the capabilities described herein.

This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI will be treated as business confidential information. Nonetheless, submitters should properly mark their responses if the information is confidential. Responses to the RFI will not be returned. Responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expense associated with responding to this RFI.

RFI Response and due date: 24 January 2019

Instructions to Responders:

Responses from all capable and qualified sources are encouraged to respond to this request.

White papers should adhere to the following formatting and outline instructions:

1. All submissions shall be made electronically and be in one of the following formats: Microsoft Word or Adobe PDF.

2. Cover Page (1page)
• Title
• Organization
• Responders technical and administrative points of contact (names, addresses, phone, fax number and email addresses)
• Topic area(s) addressed

3. Completed Attachment 1 and Attachment 2. Please note that the response shall provide sufficient technical data to determine how you fully meet the requirements as specified in Attachment 2.

Please note that responses are due no later than 24 January 2019, 3:00pm, Eastern. The preferred method of submission is via email. The point of contact for this action is Dawn Jennings, Contract Specialist, dawn.v.jennings.civ@mail.mil. Only electronic responses are requested. No evaluation letters and/or results will be issued to the respondents. At this time no solicitation exists; therefore, please do not request a copy of the solicitation. NO PHONE CALLS PLEASE. It is the responsibility of any potential offeror to monitor this site for the release of any solicitation or synopsis.

Background/Overview: WRAIR is seeking sources that can provide Fresh human A+ RBCs and plasma in CPD, collected from a donor pool whose blood products have been tested and found to support the in vitro culturing of Plasmodium falciparum isolates used in the Experimental Therapeutics (WRAIR) anti‐malarial drug screen. In the Department of Drug Discovery laboratory at the WRAIR, donor blood and plasma undergo rigorous quality control to support the growth of this parasite using totally aseptic conditions and specialized culture medium in microaerophilic atmospheres. All donor blood and plasma must be collected, tested, and found negative for CHAGAS, HBsAG, HBV‐NAT, HIV ½, HCV, HCV‐NAT, HIV‐1 NAT, WNV, and Syphilis according to the FDA (Food and Drug Administration) and all applicable Federal, State and Local regulations.

.